<div id="readability-page-1"><div><p>As global markets rally, the ASX has shown resilience against September's usual bearish trends, buoyed by recent rate cuts and economic signals from major financial institutions. In this context, penny stocks—though a somewhat outdated term—continue to offer intriguing opportunities for investors looking to explore smaller or newer companies with growth potential. While these stocks often come with risks, those backed by strong financial health can provide significant upside potential, making them worth watching in today's market landscape.</p><h3>Top 10 Penny Stocks In Australia</h3><table><tbody><tr><td><strong>Name</strong></td><td><strong>Share Price</strong></td><td><strong>Market Cap</strong></td><td><strong>Rewards &amp; Risks</strong></td></tr><tr><td>Alfabs Australia (ASX:AAL)</td><td>A$0.49</td><td>A$140.43M</td><td>✅ 4 ⚠️ 3 View Analysis &gt;</td></tr><tr><td>EZZ Life Science Holdings (ASX:EZZ)</td><td>A$2.18</td><td>A$102.84M</td><td>✅ 3 ⚠️ 2 View Analysis &gt;</td></tr><tr><td>Dusk Group (ASX:DSK)</td><td>A$0.815</td><td>A$50.75M</td><td>✅ 4 ⚠️ 2 View Analysis &gt;</td></tr><tr><td>IVE Group (ASX:IGL)</td><td>A$2.67</td><td>A$412.55M</td><td>✅ 4 ⚠️ 3 View Analysis &gt;</td></tr><tr><td>MotorCycle Holdings (ASX:MTO)</td><td>A$3.50</td><td>A$258.32M</td><td>✅ 4 ⚠️ 2 View Analysis &gt;</td></tr><tr><td>Pureprofile (ASX:PPL)</td><td>A$0.043</td><td>A$50.3M</td><td>✅ 3 ⚠️ 1 View Analysis &gt;</td></tr><tr><td>Veris (ASX:VRS)</td><td>A$0.075</td><td>A$38.83M</td><td>✅ 4 ⚠️ 2 View Analysis &gt;</td></tr><tr><td>West African Resources (ASX:WAF)</td><td>A$3.04</td><td>A$3.47B</td><td>✅ 4 ⚠️ 1 View Analysis &gt;</td></tr><tr><td>Praemium (ASX:PPS)</td><td>A$0.76</td><td>A$363.06M</td><td>✅ 5 ⚠️ 2 View Analysis &gt;</td></tr><tr><td>Service Stream (ASX:SSM)</td><td>A$2.30</td><td>A$1.41B</td><td>✅ 3 ⚠️ 1 View Analysis &gt;</td></tr></tbody></table><p>Click here to see the full list of 427 stocks from our  ASX Penny Stocks screener.</p><p>Let's explore several standout options from the results in the screener.</p><h2>Archer Materials (ASX:AXE)</h2><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p><p><strong>Overview:</strong> Archer Materials Limited is a technology company focused on developing and commercializing semiconductor devices and sensors for quantum computing, medical diagnostics, TMR sensors, and lab-on-a-chip technologies in Australia, with a market cap of A$75.18 million.</p><p><strong>Operations:</strong> The company generates revenue of A$2.06 million from its Materials Technology Research and Development segment.</p><p><strong>Market Cap:</strong> A$75.18M</p><p>Archer Materials Limited, a technology company in the semiconductor sector, remains pre-revenue with A$2.8 million reported for the year ending June 2025. Despite being unprofitable, with a net loss of A$6.97 million, it maintains financial stability through its debt-free status and sufficient cash runway exceeding three years based on current free cash flow. The company's short-term assets significantly surpass its liabilities, indicating sound liquidity management. However, earnings have declined by 10.1% annually over five years and shareholder dilution has been minimal recently amidst stable weekly volatility of 10%.</p><ul><li>Take a closer look at Archer Materials' potential here in our financial health report.</li><li>Explore historical data to track Archer Materials' performance over time in our past results report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9020cb3c-7ddc-42da-92a4-c32aac24964a/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9020cb3c-7ddc-42da-92a4-c32aac24964a/chart/financial-position-analysis"/><figcaption>ASX:AXE Financial Position Analysis as at Sep 2025</figcaption></figure><h2>Peet (ASX:PPC)</h2><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> Peet Limited acquires, develops, and markets residential land in Australia with a market cap of A$833.32 million.</p><p><strong>Operations:</strong> The company's revenue is derived from Funds Management (A$56.39 million), Joint Arrangements (A$51.88 million), and Company Owned Projects (A$313.24 million).</p><p><strong>Market Cap:</strong> A$833.32M</p><p>Peet Limited has demonstrated robust financial growth with its earnings increasing by 60% over the past year, surpassing both its five-year average and industry benchmarks. The company's net profit margins have improved, supported by a disciplined strategic approach and favorable market conditions in the Australian residential property sector. Despite high debt levels, Peet's interest payments are well-covered by EBIT, indicating manageable financial obligations. The company is currently undergoing a strategic review led by Goldman Sachs to optimize its asset base and leverage market opportunities further. Recent dividend increases reflect Peet's commitment to returning value to shareholders amidst stable weekly volatility.</p><ul><li>Click to explore a detailed breakdown of our findings in Peet's financial health report.</li><li>Review our historical performance report to gain insights into Peet's track record.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/993b423f-f3f9-4d37-9bcf-21b98c0b895b/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/993b423f-f3f9-4d37-9bcf-21b98c0b895b/chart/financial-position-analysis"/><figcaption>ASX:PPC Financial Position Analysis as at Sep 2025</figcaption></figure><h2>XRF Scientific (ASX:XRF)</h2><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p><p><strong>Overview:</strong> XRF Scientific Limited manufactures and markets precious metal products, specialized chemicals, and instruments for the scientific, analytical, construction material, and mining industries across Australia, Canada, and Europe with a market cap of A$306.01 million.</p><p><strong>Operations:</strong> The company's revenue is derived from three main segments: Consumables (A$19.26 million), Precious Metals (A$21.51 million), and Capital Equipment (A$22.56 million).</p><p><strong>Market Cap:</strong> A$306.01M</p><p>XRF Scientific Limited has shown consistent financial performance with earnings growing at 20.3% annually over the past five years, though recent growth of 16.9% did not outperform the industry average. The company maintains a strong balance sheet, with short-term assets significantly exceeding both long and short-term liabilities, and debt well-covered by operating cash flow. Despite significant insider selling recently, XRF's management and board are experienced with lengthy tenures averaging over 12 years. Recent inclusion in the S&amp;P Global BMI Index and dividend increases indicate positive market sentiment as net profit margins have improved from last year.</p><ul><li>Dive into the specifics of XRF Scientific here with our thorough balance sheet health report.</li><li>Learn about XRF Scientific's future growth trajectory here.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9b63580b-4082-4ba3-bd48-ba43082e3621/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9b63580b-4082-4ba3-bd48-ba43082e3621/chart/debt-equity-history-analysis"/><figcaption>ASX:XRF Debt to Equity History and Analysis as at Sep 2025</figcaption></figure><h2>Taking Advantage</h2><ul><li>Unlock our comprehensive list of 427  ASX Penny Stocks by clicking here.</li><li>Searching for a Fresh Perspective? Outshine the giants: these 24 early-stage AI stocks could fund your retirement.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation. We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

<p>The ASX is showing resilience amid global market rallies, with penny stocks presenting intriguing investment opportunities. Notable stocks under A$900M market cap include Alfabs Australia (A$140.43M), EZZ Life Science Holdings (A$102.84M), and Dusk Group (A$50.75M). Archer Materials (A$75.18M) focuses on semiconductor technology but remains pre-revenue. Peet Limited (A$833.32M) has seen a 60% earnings increase, while XRF Scientific (A$306.01M) maintains strong financial health with consistent growth. Investors are encouraged to explore these options in the current market landscape.</p>

3 ASX Penny Stocks With Market Caps Under A$900M To Watch